BR112016027196B1 - Vetor e cepa bacteriana gram-negativa recombinante - Google Patents

Vetor e cepa bacteriana gram-negativa recombinante Download PDF

Info

Publication number
BR112016027196B1
BR112016027196B1 BR112016027196-3A BR112016027196A BR112016027196B1 BR 112016027196 B1 BR112016027196 B1 BR 112016027196B1 BR 112016027196 A BR112016027196 A BR 112016027196A BR 112016027196 B1 BR112016027196 B1 BR 112016027196B1
Authority
BR
Brazil
Prior art keywords
protein
proteins
bacterial strain
t3ss
gram
Prior art date
Application number
BR112016027196-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016027196A2 (pt
Inventor
Cécile Arrieumerlou
Simon Ittig
Original Assignee
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Basel filed Critical Universität Basel
Publication of BR112016027196A2 publication Critical patent/BR112016027196A2/pt
Publication of BR112016027196B1 publication Critical patent/BR112016027196B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/255—Salmonella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112016027196-3A 2014-05-21 2015-05-20 Vetor e cepa bacteriana gram-negativa recombinante BR112016027196B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169335 2014-05-21
EP14169335.8 2014-05-21
PCT/EP2015/061086 WO2015177197A1 (en) 2014-05-21 2015-05-20 Bacteria-based protein delivery

Publications (2)

Publication Number Publication Date
BR112016027196A2 BR112016027196A2 (pt) 2018-01-30
BR112016027196B1 true BR112016027196B1 (pt) 2023-05-02

Family

ID=50771120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027196-3A BR112016027196B1 (pt) 2014-05-21 2015-05-20 Vetor e cepa bacteriana gram-negativa recombinante

Country Status (23)

Country Link
US (3) US10889823B2 (cg-RX-API-DMAC7.html)
EP (2) EP3660034A1 (cg-RX-API-DMAC7.html)
JP (3) JP6797025B2 (cg-RX-API-DMAC7.html)
KR (2) KR102648293B1 (cg-RX-API-DMAC7.html)
CN (2) CN107001431B (cg-RX-API-DMAC7.html)
AU (1) AU2015261905B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027196B1 (cg-RX-API-DMAC7.html)
CA (1) CA2948570C (cg-RX-API-DMAC7.html)
CY (1) CY1122701T1 (cg-RX-API-DMAC7.html)
DK (1) DK3145946T3 (cg-RX-API-DMAC7.html)
EA (1) EA201692025A1 (cg-RX-API-DMAC7.html)
ES (1) ES2754508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192050T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046025T2 (cg-RX-API-DMAC7.html)
IL (2) IL248827B (cg-RX-API-DMAC7.html)
LT (1) LT3145946T (cg-RX-API-DMAC7.html)
PL (1) PL3145946T3 (cg-RX-API-DMAC7.html)
PT (1) PT3145946T (cg-RX-API-DMAC7.html)
RS (1) RS59583B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201609629YA (cg-RX-API-DMAC7.html)
SI (1) SI3145946T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900626T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015177197A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001431B (zh) 2014-05-21 2022-11-01 巴塞尔大学 基于细菌的蛋白质递送
WO2017087827A1 (en) * 2015-11-19 2017-05-26 President And Fellows Of Harvard College Method of making recombinant silk andsilk-amyloid hybrid proteins using bacteria
SMT202000620T1 (it) * 2015-11-19 2021-01-05 Univ Basel Distribuzione di proteine basata su batteri
EA201890868A1 (ru) 2015-11-19 2018-12-28 Университет Базель Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
US12351805B2 (en) 2015-11-19 2025-07-08 Northeastern University Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
JP6976351B2 (ja) 2016-12-20 2021-12-08 ウニヴェルズィテート・バーゼルUniversitat Basel 弱毒化細菌に基づくタンパク質送達
US11484603B2 (en) 2017-03-31 2022-11-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods, systems, and compositions for inhibiting virulence of A/E family pathogens
CN107858367A (zh) * 2017-12-05 2018-03-30 复旦大学附属肿瘤医院 一种利用细菌靶向投递治疗性蛋白的系统及其应用
CN114401730A (zh) * 2019-05-01 2022-04-26 因内特生物制品有限责任公司 免疫调节组合物和方法
EP4045672A4 (en) * 2019-10-18 2023-11-22 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR PRODUCING ENHANCED IMMUNE RESPONSES AND RAPID ANTIBODY PRODUCTION
CN111848803B (zh) * 2020-07-21 2022-04-08 珠海中科先进技术研究院有限公司 一种具有突出酸碱稳定性的磷脂酰肌醇蛋白聚糖3的纳米抗体及其制备方法
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用
IL302334A (en) * 2020-10-27 2023-06-01 T3 Pharmaceuticals Ag Providing bacteria-based protein
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用
CN115896314A (zh) * 2022-07-14 2023-04-04 四川大学 一种基于lf-rpa的猕猴桃细菌性溃疡病菌的无设备、可视化检测方法
CN117511912B (zh) * 2023-12-22 2024-03-29 辉大(上海)生物科技有限公司 IscB多肽、包含其的系统及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US6596509B1 (en) * 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
AU2002312778A1 (en) * 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
FR2862312B1 (fr) * 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
JP2009501357A (ja) 2005-07-15 2009-01-15 レアード テクノロジーズ マップ カンパニー リミテッド 小型カメラ用開閉装置
US8357373B2 (en) 2005-10-04 2013-01-22 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) * 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
EP2268313A2 (en) * 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
WO2010135563A1 (en) * 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−4受容体結合融合タンパク質及びその使用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CN107001431B (zh) 2014-05-21 2022-11-01 巴塞尔大学 基于细菌的蛋白质递送
EA201890868A1 (ru) 2015-11-19 2018-12-28 Университет Базель Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
SMT202000620T1 (it) 2015-11-19 2021-01-05 Univ Basel Distribuzione di proteine basata su batteri
JP6976351B2 (ja) 2016-12-20 2021-12-08 ウニヴェルズィテート・バーゼルUniversitat Basel 弱毒化細菌に基づくタンパク質送達

Also Published As

Publication number Publication date
SMT201900626T1 (it) 2020-01-14
JP7509821B2 (ja) 2024-07-02
ES2754508T3 (es) 2020-04-17
JP2020182478A (ja) 2020-11-12
RS59583B1 (sr) 2019-12-31
KR102648293B1 (ko) 2024-03-15
KR20220127345A (ko) 2022-09-19
HUE046025T2 (hu) 2020-01-28
CN107001431A (zh) 2017-08-01
CN115960919A (zh) 2023-04-14
US20210155942A1 (en) 2021-05-27
CN107001431B (zh) 2022-11-01
KR102440293B1 (ko) 2022-09-05
KR20170010803A (ko) 2017-02-01
EA201692025A1 (ru) 2017-05-31
IL283280B1 (en) 2023-04-01
JP2017517257A (ja) 2017-06-29
BR112016027196A2 (pt) 2018-01-30
AU2015261905B2 (en) 2020-07-09
IL248827A0 (en) 2017-01-31
PL3145946T3 (pl) 2020-02-28
AU2015261905A1 (en) 2016-12-01
IL283280B2 (en) 2023-08-01
JP2022109967A (ja) 2022-07-28
US12091670B2 (en) 2024-09-17
HRP20192050T1 (hr) 2020-02-07
SI3145946T1 (sl) 2019-12-31
US20170198297A1 (en) 2017-07-13
CA2948570A1 (en) 2015-11-26
EP3145946A1 (en) 2017-03-29
IL248827B (en) 2021-07-29
EP3660034A1 (en) 2020-06-03
US10889823B2 (en) 2021-01-12
IL283280A (en) 2021-07-29
DK3145946T3 (da) 2019-11-18
PT3145946T (pt) 2019-11-20
LT3145946T (lt) 2019-11-25
US20240401065A1 (en) 2024-12-05
EP3145946B1 (en) 2019-08-14
SG11201609629YA (en) 2016-12-29
CY1122701T1 (el) 2021-03-12
WO2015177197A1 (en) 2015-11-26
CA2948570C (en) 2023-09-12
JP6797025B2 (ja) 2020-12-09

Similar Documents

Publication Publication Date Title
US12091670B2 (en) Bacteria-based protein delivery
EP3377634B1 (en) Bacteria-based protein delivery
CA3005380C (en) Bacteria-based protein delivery
EA041646B1 (ru) Доставка белков, осуществляемая на основе бактерий
HK1236208A1 (en) Bacteria-based protein delivery
HK1236208B (en) Bacteria-based protein delivery
BR112018009782B1 (pt) Cepas bacterianas recombinantes gram-negativas transformadas com um vetor e vetores
HK1256138B (en) Bacteria-based protein delivery

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023002172-0 PROTOCOLO 870230010380 EM 06/02/2023 11:26.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/05/2015, OBSERVADAS AS CONDICOES LEGAIS